Systemic Scleroderma Treatment Market

Systemic scleroderma is a systemic autoimmune disease characterized by localized or diffuse skin thickening and fibrosis. The lesions were characterized by fibrous hyperplasia and onion like changes in blood vessels, which eventually led to skin sclerosis and vascular ischemia. This disease is characterized by localized or diffuse skin thickening and fibrosis. In addition to skin involvement, it can also affect visceral organs (such as heart, lung and digestive tract). As an autoimmune disease, it is often accompanied by autoantibodies such as antinuclear antibody, anti centromere antibody and anti ScL-70. The incidence rate of this disease is more than 4 times that of men, and children are relatively rare.

Systemic Scleroderma Treatment Market contains market size and forecasts of Systemic Scleroderma Treatment in Global, including the following market information:

Global Systemic Scleroderma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Systemic Scleroderma Treatment market was valued at 1604.4 million in 2021 and is projected to reach US$ 2149.7 million by 2028, at a CAGR of 4.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immunosuppressors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Systemic Scleroderma Treatment include Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc. and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Systemic Scleroderma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Systemic Scleroderma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, by Type, 2021 (%)

Immunosuppressors

Phosphodiesterase 5 inhibitors - PHA

Endothelin Receptor Antagonists

Prostacyclin Analogues

Calcium Channel Blockers

Others

Global Systemic Scleroderma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, by Application, 2021 (%)

Skin

Bones and Joints

Digestive System

Lung

Heart

Kidney

Global Systemic Scleroderma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Systemic Scleroderma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Systemic Scleroderma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boehringer Ingelheim International GmbH

Gilead Sciences Inc.

GlaxoSmithKline plc

Novartis AG

Pfizer Inc.

Bayer AG